Track market-moving stories before they get noisy

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) CFO Cristina Gallo-Aquino will present a company update at the Morgan Stanley 14th Annual Laguna Conference. Who: Ryder System, Inc. Executive Vice President & CFO Cristina Gallo-Aquino What: Morgan Stanley 14th Annual Laguna Conference When: Wednesday, September 16, 2026 Time: 1:50 p.m. Pacific Time Webcast: To access the live webcast, visit http://investors.ryder.com. About Ryder System, Inc. Ryder System, Inc. (NYSE: R) is a nearly $13.

NEOS Investments, an asset management firm comprised of leaders and pioneers in the options-based ETF space, announces August monthly distribution amounts for their suite of ETFs that pursue monthly income and tax efficiency across core portfolio exposures.

August 2026 Distribution Information, based on each ETFs Ex-Dividend Date:

Distribution

Rate*

Amount /

Share (%)

Amount /

Share ($)

Ex-Dividend Date

30-Day SEC Yield**

Boosted Bitcoin High Income ETF (XBCI)

38.83%

3.24%

$1.0257

8/5/26

1.52%

Ethereum High Income ETF (NEHI)

30.24%

2.52%

$0.7184

8/19/26

1.50%

Bitcoin High Income ETF (BTCI)

25.61%

2.13%

$0.6289

8/19/26

1.62%

Boosted Nasdaq-100 High Income ETF (XQQI)

20.15%

1.68%

$0.8236

8/5/26

-0.34%

Boosted S&P 500 High Income ETF (XSPI)

16.78%

1.40%

$0.6994

8/5/26

0.19%

Russell 2000 High Income ETF (IWMI)

14.51%

1.21%

$0.6373

8/19/26

0.52%

Nasdaq-100 High Income ETF (QQQI)

14.39%

1.20%

$0.6518

8/19/26

-0.04%

MLP & Energy Infrastructure High Income ETF (MLPI)

14.19%

1.18%

$0.6402

8/19/26

3.38%

S&P 500 High Income ETF (SPYI)

12.15%

1.01%

$0.5423

8/19/26

0.47%

Gold High Income ETF (IAUI)

11.98%

1.00%

$0.5182

8/19/26

1.98%

Real Estate High Income ETF (IYRI)

10.84%

0.90%

$0.4461

8/19/26

2.97%

MSCI EAFE High Income ETF (NIHI)

9.71%

0.81%

$0.4257

8/19/26

2.82%

Nasdaq-100 Hedged Equity Income ETF (QQQH)

9.02%

0.75%

$0.4084

8/26/26

-0.04%

Enhanced Income Credit Select ETF (HYBI)

8.08%

0.67%

$0.3291

8/12/26

6.00%

S&P 500 Hedged Equity Income ETF (SPYH)

7.84%

0.65%

$0.3682

8/26/26

0.49%

Enhanced Income 20+ Year Treasury Bond ETF (TLTI)

6.27%

0.52%

$0.2267

8/12/26

4.71%

Enhanced Income Aggregate Bond ETF (BNDI)

5.78%

0.48%

$0.2227

8/12/26

3.52%

Long/Short Equity Income ETF (NLSI)

5.27%

0.44%

$0.2465

8/26/26

-0.74%

Enhanced Income 1-3 Month T-Bill ETF (CSHI)

5.00%

0.42%

$0.2069

8/12/26

3.25%

Average Annual Returns (%) as of Most Recent Quarter-End (6/30/2026)

Fund Name

Inception

Date

Ticker

Type

1 Year

5

Year

10

Year

Inception

NEOS Enhanced Income Aggregate Bond ETF

8/29/2022

BNDI

MKT

5.27

-

-

4.08

NEOS Enhanced Income Aggregate Bond ETF

8/29/2022

BNDI

NAV

5.57

-

-

4.09

NEOS Bitcoin High Income ETF

10/16/2024

BTCI

MKT

-40.95

-

-

-7.50

NEOS Bitcoin High Income ETF

10/16/2024

BTCI

NAV

-40.91

-

-

-7.65

NEOS Enhanced Income 1-3 Month T-Bill ETF

8/29/2022

CSHI

MKT

5.16

-

-

5.48

NEOS Enhanced Income 1-3 Month T-Bill ETF

8/29/2022

CSHI

NAV

5.10

-

-

5.47

NEOS Enhanced Cr Select ETF

9/30/2014

HYBI

MKT

5.92

3.46

4.35

4.17

NEOS Enhanced Cr Select ETF

9/30/2014

HYBI

NAV

5.87

3.47

4.36

4.18

NEOS Gold High Income ETF

6/4/2025

IAUI

MKT

12.04

-

-

10.12

NEOS Gold High Income ETF

6/4/2025

IAUI

NAV

12.01

-

-

10.01

NEOS Russell 2000 High Income ETF

6/24/2024

IWMI

MKT

35.91

-

-

20.07

NEOS Russell 2000 High Income ETF

6/24/2024

IWMI

NAV

36.26

-

-

20.18

NEOS Real Estate High Income ETF

1/14/2025

IYRI

MKT

9.54

-

-

10.82

NEOS Real Estate High Income ETF

1/14/2025

IYRI

NAV

9.68

-

-

10.77

NEOS MLP & Energy Infrastructure High Income ETF

12/17/2025

MLPI

MKT

-

-

-

19.96

NEOS MLP & Energy Infrastructure High Income ETF

12/17/2025

MLPI

NAV

-

-

-

19.68

NEOS Ethereum High Income ETF

12/2/2025

NEHI

MKT

-

-

-

-42.40

NEOS Ethereum High Income ETF

12/2/2025

NEHI

NAV

-

-

-

-42.87

NEOS MSCI EAFE High Income ETF

9/16/2025

NIHI

MKT

-

-

-

12.46

NEOS MSCI EAFE High Income ETF

9/16/2025

NIHI

NAV

-

-

-

12.41

NEOS Long/Short Equity Income ETF

12/9/2025

NLSI

MKT

-

-

-

5.30

NEOS Long/Short Equity Income ETF

12/9/2025

NLSI

NAV

-

-

-

5.28

NEOS NASDAQ-100 Hedged Equity Income ETF

12/19/2019

QQQH

MKT

16.78

8.40

-

10.39

NEOS NASDAQ-100 Hedged Equity Income ETF

12/19/2019

QQQH

NAV

16.85

8.47

-

10.42

NEOS Nasdaq 100 High Income ETF

1/29/2024

QQQI

MKT

25.70

-

-

21.50

NEOS Nasdaq 100 High Income ETF

1/29/2024

QQQI

NAV

25.99

-

-

21.63

NEOS S&P 500 Hedged Equity Income ETF

4/2/2025

SPYH

MKT

14.97

-

-

18.00

NEOS S&P 500 Hedged Equity Income ETF

4/2/2025

SPYH

NAV

14.97

-

-

17.95

NEOS S&P 500 (R) High Income ETF

8/29/2022

SPYI

MKT

18.97

-

-

14.81

NEOS S&P 500 (R) High Income ETF

8/29/2022

SPYI

NAV

19.02

-

-

14.86

NEOS Enhanced Income 20+ Year Treasury Bond ETF

12/10/2024

TLTI

MKT

3.89

-

-

0.58

NEOS Enhanced Income 20+ Year Treasury Bond ETF

12/10/2024

TLTI

NAV

4.01

-

-

0.42

NEOS Boosted Bitcoin High Income ETF

2/2/2026

XBCI

MKT

-

-

-

-29.38

NEOS Boosted Bitcoin High Income ETF

2/2/2026

XBCI

NAV

-

-

-

-30.35

NEOS Boosted Nasdaq-100 High Income ETF

2/2/2026

XQQI

MKT

-

-

-

15.94

NEOS Boosted Nasdaq-100 High Income ETF

2/2/2026

XQQI

NAV

-

-

-

15.62

NEOS Boosted S&P 500 High Income ETF

2/2/2026

XSPI

MKT

-

-

-

6.73

NEOS Boosted S&P 500 High Income ETF

2/2/2026

XSPI

NAV

-

-

-

6.48

About NEOS Investments: Founded in 2022, NEOS Investments offers ETFs that aim to deliver the next evolution of options strategies, where seeking income is the outcome. Built on decades of research and experience, NEOS ETFs aim to empower investors with portfolio building blocks that provide monthly income, tax efficiency, and diversification through data-driven options-based ETFs.

The performance data quoted above represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted above. Inception performance for funds with less than one year of history reflect cumulative returns. Standardized performance current to the most recent month-end and quarter-end can be obtained by visiting any of the corresponding ETF funds pages by clicking on their ticker: SPYI | QQQI | IWMI | QQQH | BTCI | HYBI | BNDI | CSHI| TLTI | IYRI | SPYH| IAUI| NIHI | NEHI | NLSI | MLPI | XSPI | XQQI | XBCI or calling 866.498.5677.

ETF Management Fees: XSPI, XQQI, XSPI, BTCI, NEHI, NLSI = 0.98% | IAUI = 0.78% | SPYI, QQQI, SPYH, IWMI, MLPI, NIHI, QQQH, HYBI, IYRI = 0.68% | BNDI, TLTI = 0.58% | CSHI = 0.38%

The Advisor has contractually agreed to keep the net expenses of BNDI from exceeding 0.58% of the Fund's average daily net assets through May 1, 2027 subject to approval of the agreement by the Board. Without the fee waiver the Fund expenses would be 0.61%. Additionally, the Advisor has contractually agreed to keep the net expenses of IWMI from exceeding 0.68% of the Fund's average daily net assets through May 1, 2027 subject to approval of the agreement by the Board. Without the fee waiver the Fund expenses would be 0.76%. Additionally, the Advisor has contractually agreed to keep the net expenses of HYBI from exceeding 0.68% of the Fund's average daily net assets through May 1, 2027 subject to approval of the agreement by the Board. Without the fee waiver the Fund expenses would be 0.72%. Additionally, the Advisor has contractually agreed to keep the net expenses of NIHI from exceeding 0.68% of the Fund's average daily net assets through May 1, 2027 subject to approval of the agreement by the Board. Without the fee waiver the Fund expenses would be 0.75%. The total annual fund operating expenses of NLSI are 2.89%, comprised of a 0.98% management fee and 1.91% of other expenses including dividend, interest and brokerage expenses on short positions based on estimated amounts for the Fund's current fiscal year. The total annual fund operating expenses of IAUI are 0.79%, comprised of a 0.78% management fee and 0.01% of acquired fund fees and expenses, which are the indirect costs of investing in other investment companies (including money market funds). The total annual fund operating expenses of BTCI are 0.99%, comprised of a 0.98% management fee and 0.01% of acquired fund fees and expenses, which are the indirect costs of investing in other investment companies (including money market funds).

*The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent ex-date NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. Distributions are not guaranteed.

Distributions made by the Funds have been classified as a return of capital and may be comprised of option premiums, dividends, capital gains, and interest payments. Please see the 19a-1 notices for an estimated breakdown of monthly distributions on each Fund's page.

Distributions in excess of the Fund’s current and accumulated earnings and profits are treated as a tax-free return of your investment to the extent of your basis in the Shares, and generally as capital gain thereafter. A return of capital, which for tax purposes is treated as a return of your investment, reduces your basis in Shares, thus reducing any loss or increasing any gain on a subsequent taxable disposition of Shares. A distribution will reduce the Fund’s NAV per Share and may be taxable to you as ordinary income or capital gain even though, from an economic standpoint, the distribution may constitute a return of capital.

**30-day SEC Yield is calculation based on a formula mandated by the Securities and Exchange Commission (SEC) that calculates a fund's hypothetical annualized income, as a percentage of its assets. A security's income, for the purposes of this calculation, is based on the current market yield to maturity (in the case of bonds) or projected dividend yield (for stocks) of the fund's holdings over a trailing 30-day period. This hypothetical income will differ (at times, significantly) from the fund's actual experience; as a result, income distributions from the fund may be higher or lower than implied by the SEC yield. It is important to note that 30-Day SEC Yield does not include income received from option selling. The data reflects the most recent month-end (07/31/2026). The Unsubsidized 30-day SEC Yield represents what a fund’s 30-day SEC yield would be had no fee waiver been in place over the reporting period. BNDI = 3.49%, HYBI = 5.97%, IWMI = 0.46%, NIHI = 2.74%.

Investors should carefully consider the investment objectives, risks, charges and expenses of Exchange Traded Funds (ETFs) before investing. To obtain an ETF's prospectus containing this and other important information, please call (866) 498-5677 or view/download a prospectus by clicking on the corresponding ETF ticker: SPYI | QQQI | IWMI | QQQH | BTCI | HYBI | BNDI | CSHI| TLTI| IYRI | SPYH| IAUI| NIHI | NEHI | NLSI | MLPI | XSPI | XQQI | XBCI. Please read the prospectus carefully before you invest.

An investment in NEOS ETFs involves risk, including possible loss of principal. The equity securities purchased by the Funds may involve large price swings and potential for loss. Investments in smaller companies typically exhibit higher volatility. Investors in the ETFs should be willing to accept a high degree of volatility in the price of fund shares and the possibility of significant losses.

The use of derivative instruments involves risks different from, or possibly greater than, the risks associated with investing directly in securities and other traditional investments. These risks include (i) the risk that the counterparty to a derivative transaction may not fulfill its contractual obligations; (ii) risk of mispricing or improper valuation; and (iii) the risk that changes in the value of the derivative may not correlate perfectly with the underlying asset, rate or index. Derivative prices are highly volatile and may fluctuate substantially during a short period of time. The use of leverage by the Fund, such as borrowing money to purchase securities or the use of options, will cause the Fund to incur additional expenses and magnify the Fund’s gains or losses. The earnings and prospects of small and medium-sized companies are more volatile than larger companies and may experience higher failure rates than larger companies. Small and medium sized companies normally have a lower trading volume than larger companies, which may tend to make their market price fall more disproportionately than larger companies in response to selling pressures and may have limited markets, product lines, or financial resources and lack management experience. The funds are new with a limited operating history.

The information on this website does not constitute investment advice or a recommendation of any products, strategies, or services. Investors should consult with a financial professional regarding their individual circumstances before making investment decisions. NEOS Investments or its affiliates, nor Foreside Fund Services, LLC, or its affiliates accept any responsibility for loss arising from the use of the information contained herein.

NEOS ETFs are distributed by Foreside Fund Services, LLC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901443033/en/

Callan Family Office LLC bought a new position in shares of Ryder System, Inc. (NYSE:R – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,079 shares of the transportation company’s stock, valued at approximately $812,000.

A number of other institutional investors have also recently added to or reduced their stakes in R. Keating Financial Advisory Services Inc. bought a new position in Ryder System during the 2nd quarter valued at $26,000. Allworth Financial LP bought a new stake in shares of Ryder System in the 2nd quarter worth $11,498,000. Advisors Preferred LLC bought a new stake in shares of Ryder System in the 2nd quarter worth $1,974,000. Vise Technologies Inc. acquired a new stake in shares of Ryder System in the second quarter valued at $1,502,000. Finally, Denali Advisors LLC acquired a new stake in shares of Ryder System in the second quarter valued at $609,000. 87.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In A number of research analysts recently issued reports on R shares. Wells Fargo & Company lifted their target price on Ryder System from $290.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Zacks Research cut shares of Ryder System from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 22nd. Wall Street Zen raised shares of Ryder System from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Morgan Stanley raised their price objective on shares of Ryder System from $263.00 to $280.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ryder System from $259.00 to $296.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Ryder System currently has a consensus rating of “Moderate Buy” and an average target price of $294.14.

View Our Latest Analysis on R Ryder System Stock Performance R opened at $244.93 on Tuesday. The firm has a market cap of $9.39 billion, a PE ratio of 19.93 and a beta of 1.02. The company has a quick ratio of 0.65, a current ratio of 0.65 and a debt-to-equity ratio of 1.91. The business has a fifty day simple moving average of $263.78 and a 200-day simple moving average of $239.24. Ryder System, Inc. has a fifty-two week low of $157.67 and a fifty-two week high of $284.25.

Ryder System (NYSE:R – Get Free Report) last issued its earnings results on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.69 by $0.04. Ryder System had a return on equity of 18.28% and a net margin of 3.88%.The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the firm posted $3.32 EPS. The company’s quarterly revenue was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. As a group, equities analysts predict that Ryder System, Inc. will post 14.74 EPS for the current fiscal year.

Ryder System Increases Dividend The business also recently declared a quarterly dividend, which will be paid on Friday, September 18th. Investors of record on Monday, August 24th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a yield of 1.6%. This is an increase from Ryder System’s previous quarterly dividend of $0.91. Ryder System’s dividend payout ratio (DPR) is 29.62%.

Insider Transactions at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $251.95, for a total transaction of $149,910.25. Following the completion of the sale, the senior vice president directly owned 22,948 shares of the company’s stock, valued at approximately $5,781,748.60. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.90% of the company’s stock.

Ryder System Profile (Free Report)

Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.

Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.

Featured Articles Five stocks we like better than Ryder System Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.

Algert Global LLC lowered its holdings in shares of Ryder System, Inc. (NYSE:R – Free Report) by 14.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,455 shares of the transportation company’s stock after selling 8,840 shares during the period. Algert Global LLC owned approximately 0.13% of Ryder System worth $13,572,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of R. Royal Bank of Canada increased its stake in Ryder System by 52.8% during the 1st quarter. Royal Bank of Canada now owns 15,765 shares of the transportation company’s stock valued at $2,267,000 after purchasing an additional 5,448 shares in the last quarter. Focus Partners Wealth lifted its holdings in Ryder System by 7.9% during the first quarter. Focus Partners Wealth now owns 1,851 shares of the transportation company’s stock worth $266,000 after acquiring an additional 135 shares during the period. Geneos Wealth Management Inc. raised its stake in shares of Ryder System by 61.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 287 shares of the transportation company’s stock worth $41,000 after purchasing an additional 109 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Ryder System by 10.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,191 shares of the transportation company’s stock valued at $189,000 after acquiring an additional 110 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in Ryder System by 10.9% during the second quarter. M&T Bank Corp now owns 2,153 shares of the transportation company’s stock valued at $343,000 after purchasing an additional 212 shares during the period. 87.47% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on R shares. Stephens upgraded shares of Ryder System to a “strong-buy” rating in a research note on Wednesday, July 8th. Wells Fargo & Company raised their price target on Ryder System from $290.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Ryder System in a report on Wednesday, May 27th. Barclays upped their target price on Ryder System from $290.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Citigroup upped their price target on shares of Ryder System from $280.00 to $283.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Ryder System has a consensus rating of “Moderate Buy” and an average target price of $294.14.

Read Our Latest Report on Ryder System Insiders Place Their Bets In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of Ryder System stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $251.95, for a total value of $149,910.25. Following the completion of the transaction, the senior vice president directly owned 22,948 shares of the company’s stock, valued at approximately $5,781,748.60. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.90% of the company’s stock.

Ryder System Stock Performance Shares of R opened at $246.00 on Wednesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.65 and a quick ratio of 0.65. Ryder System, Inc. has a one year low of $157.67 and a one year high of $284.25. The firm has a market capitalization of $9.43 billion, a PE ratio of 20.02 and a beta of 1.02. The company has a 50-day simple moving average of $263.20 and a two-hundred day simple moving average of $239.47.

Ryder System (NYSE:R – Get Free Report) last announced its earnings results on Thursday, July 23rd. The transportation company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.69 by $0.04. Ryder System had a net margin of 3.88% and a return on equity of 18.28%. The firm had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the previous year, the business posted $3.32 EPS. The company’s quarterly revenue was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. On average, analysts anticipate that Ryder System, Inc. will post 14.74 EPS for the current fiscal year.

Ryder System Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Stockholders of record on Monday, August 24th will be paid a $1.01 dividend. This is an increase from Ryder System’s previous quarterly dividend of $0.91. This represents a $4.04 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, August 24th. Ryder System’s payout ratio is currently 32.87%.

About Ryder System (Free Report)

Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.

Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.

Read More Five stocks we like better than Ryder System Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize

Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.

MIDLAND, VA / ACCESS Newswire / August 26, 2026 / Smith-Midland Corporation (NASDAQ:SMID), a leading manufacturer of innovative precast concrete products for transportation, infrastructure, and building construction, has been awarded a $2.2 million contract to manufacture and supply its SlenderWall® architectural precast wall system for the new U.S. Coast Guard Clinic and Visitors Center in Charleston, South Carolina, further expanding the company's portfolio of mission-critical government and military construction projects.

The contract further strengthens Smith-Midland's position in the architectural precast market and demonstrates demand for SlenderWall® on complex institutional and government projects. As investments in resilient infrastructure and federal facilities continue, Smith-Midland remains well positioned to provide innovative precast solutions that help owners reduce construction timelines while achieving long-lasting building performance.

"Projects like the U.S. Coast Guard Clinic and Visitors Center highlight the increasing demand for resilient, high-performance building systems that can meet the unique requirements of government and military facilities," said Matthew Smith, Vice President of Sales and Marketing for Smith-Midland Corporation. "Our SlenderWall® system combines architectural flexibility with exceptional durability and construction efficiency, making it an ideal solution for mission-critical projects."

The project features SlenderWall® panels fabricated with white and gray architectural concrete and finished with an acid-etched surface, creating a clean, modern appearance while providing the long-term performance expected of federal facilities. Production is expected to begin at Smith-Midland's Virginia manufacturing facility in April 2027, with installation scheduled to begin in November 2027.

Engineered with resilience in mind, the building's ground floor has been specifically designed to accommodate storm surge flows, improving the facility's ability to withstand severe weather events while maintaining long-term operational reliability. Smith-Midland's SlenderWall® system complements these design objectives by providing a lightweight, high-performance architectural envelope that delivers durability, energy efficiency, and accelerated construction.

The new facility is designed to support the operational and healthcare needs of the U.S. Coast Guard by housing medical and dental services, work-life staff offices, and counseling areas. The project also includes a new entry control point featuring a guard house and visitor check-in center to enhance campus security and visitor access.

About Smith-Midland Corporation

Smith-Midland develops, manufactures, licenses, rents, and sells a broad array of precast concrete products for use primarily in the construction, transportation, and utility industries.

Smith-Midland Corporation has three manufacturing facilities in: Midland, VA, Reidsville, NC, and Columbia, SC, and a J-J Hooks® Safety Barrier rental firm, Concrete Safety Systems. Easi-Set Worldwide, a wholly owned subsidiary of Smith-Midland Corporation, licenses the production and sale of Easi-Set products, including J-J Hooks and SlenderWall®, and provides diversification opportunities to the precast industry worldwide. For more information, please call (540) 439-3266 or visit www.smithmidland.com.

Forward-Looking Statements

This announcement contains forward-looking statements, which involve risks and uncertainties. The Company's actual results may differ significantly from those discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, product demand, the impact of competitive products and pricing, capacity and supply constraints or difficulties, the uncertainties arising from the policies of the government, the risk of less government spending on infrastructure than anticipated, inflationary factors including potential recession, our material weaknesses in internal controls, cyber security risks, general business and economic conditions, our high level of accounts receivables, the effect of the Company's accounting policies and other risks detailed in the Company's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

Media Inquiries:
Sarah Crandall
[email protected]
(540) 439-8056

Sales Inquiries:
[email protected]
(540) 439-3266

Investor Relations:
Steven Hooser or John Beisler
Three Part Advisors, LLC
[email protected]
[email protected]
(214) 872-2710

SOURCE: Smith-Midland Corporation

Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500 units ("Units") at a price of C$0.24 per Unit ("Offering Price") for aggregate gross proceeds of C$3,555,000. The Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").

Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share ("Warrant Share") at an exercise price of C$0.32 per Warrant Share at any time until May 20, 2031. The Company has received conditional approval to list the Warrants underlying the Units and anticipates they will commence trading on the TSX Venture Exchange ("TSXV"), as part of the existing warrant class bearing the CUSIP:88337V142, under the trading symbol "TLT.WT", on or about August 27, 2026, subject to final approval from the TSXV. The Warrants are governed by the terms of a warrant indenture dated May 20, 2026, as supplemented by the supplemental indenture dated August 24, 2026 ( the "Supplemental Indenture") between the Company and TSX Trust Company of Canada ("Warrant Agent"), as Warrant Agent. The Supplemental Indenture authorized a total of 36,115,273 Warrants.

The Company plans to use the proceeds of the Offering to complete Good Laboratory Practice ("GLP") toxicology studies supporting clinical development of the intravenous use of Rutherrin® (Ruvidar® + transferrin) in the treatment of various cancers; further GLP toxicology studies supporting clinical development of the topical use of Ruvidar® in the treatment of herpes simplex virus-induced cold sores; working capital and general corporate purposes.

The Offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by CSA Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption ("Listed Issuer Financing Exemption" or "LIFE"). The securities issued under LIFE are not subject to resale restrictions pursuant to applicable Canadian securities laws and will become free trading on closing. The Offering is subject to final acceptance by the TSXV.

In consideration for their services, the Agent received an aggregate cash commission of C$216,893. The Company also issued 903,723 non-transferable compensation options to the Agent ("Compensation Options"), with each Compensation Option exercisable to acquire one Unit at an exercise price of C$0.24 per Unit until May 20, 2031.

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President, Chief Executive Officer and Chairman of the Board of Theralase®, stated that "The Company has successfully raised approximately C$11,000,000 in equity and C$1,000,000 in debt under a recurring line of credit over the last 8 months, in order to strengthen our balance sheet and provide the Company with additional capital to fund our strategic initiatives. In 2026/2027, the Company plans to complete follow-up assessments on the remaining patients in Study II, file rolling review drug applications to Health Canada and the FDA and seek Canadian and US marketing approval of its light-activated drug, Ruvidar® for bladder cancer. In addition, the Company plans to commence GLP toxicology studies on Rutherrin® to allow clinical development, subject to regulatory approval, for a number of cancer indications; including: brain, lung, pancreatic, colorectal and muscle invasive bladder cancer."

Related Party Transactions
An aggregate of 116,250 Units, representing gross proceeds of $27,900, were issued to certain insiders of the Company; these Units will be subject to the Exchange hold period of 4 months plus a day. Pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and TSX Venture Exchange Policy 5.9, such insider subscriptions constitute a related party transaction. The Company is exempt from the formal valuation requirement of MI 61-101 in connection with the insider subscriptions in reliance on section 5.5(b) of MI 61-101, as no securities of the Company are listed or quoted for trading on the Toronto Stock Exchange, the New York Stock Exchange, the American Stock Exchange, the Nasdaq Stock Market or any other stock exchange outside Canada and the United States. The Company is also exempt from obtaining minority shareholder approval in connection with the insider subscriptions in reliance on section 5.7(1)(a) of MI 61-101, as the aggregate value of the insider subscriptions does not exceed 25% of the market capitalization of the Company. Due to the limited time between the launch and closing of the Offering, there were fewer than 21 days between the date the Company filed its material change report in respect of the Offering and the closing date of the Offering.

The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act"), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for, the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States. unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirement is available. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities offered in any jurisdiction in which such offer, solicitation or sale would be unlawful; including, the United States.

About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, "FLS") within the meaning of applicable Canadian securities laws. Such statements; include, but are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the use of proceeds of the Offering; the timing for closing of the Offering; current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks to the Company include: successful commercialization of its energy-activated small molecule and drug formulations; access to sufficient capital to fund the Company's operations on terms that are commercially favorable to the Company or at all; the safety and effectiveness of the Company's small molecule and formulations against the diseases tested in its clinical studies; the failure to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings such as the final approval from the TSXV and TSXV approval to list the Warrants. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311258

Source: Theralase Technologies Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

BlackRock Inc. purchased a new stake in Ryder System, Inc. (NYSE:R – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 4,021,493 shares of the transportation company’s stock, valued at approximately $1,060,749,000. BlackRock Inc. owned approximately 10.49% of Ryder System at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of R. Calamos Wealth Management LLC bought a new position in Ryder System during the 4th quarter valued at $1,408,000. Arrowstreet Capital Limited Partnership increased its position in shares of Ryder System by 9.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 194,632 shares of the transportation company’s stock worth $39,843,000 after purchasing an additional 16,070 shares during the last quarter. Braun Stacey Associates Inc. acquired a new stake in shares of Ryder System in the 1st quarter valued at about $12,189,000. NewEdge Wealth LLC lifted its position in shares of Ryder System by 2.9% during the fourth quarter. NewEdge Wealth LLC now owns 250,334 shares of the transportation company’s stock worth $47,911,000 after purchasing an additional 6,952 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Ryder System by 23.6% during the first quarter. California State Teachers Retirement System now owns 48,030 shares of the transportation company’s stock worth $9,832,000 after purchasing an additional 9,179 shares during the last quarter. Institutional investors and hedge funds own 87.47% of the company’s stock.

Ryder System Trading Up 0.6% NYSE:R opened at $249.44 on Friday. The stock has a market cap of $9.57 billion, a PE ratio of 20.30 and a beta of 1.02. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.65 and a quick ratio of 0.65. The stock’s 50-day moving average is $264.42 and its two-hundred day moving average is $238.70. Ryder System, Inc. has a fifty-two week low of $157.67 and a fifty-two week high of $284.25.

Ryder System (NYSE:R – Get Free Report) last issued its earnings results on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.69 by $0.04. Ryder System had a net margin of 3.88% and a return on equity of 18.28%. The company had revenue of $2.69 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter last year, the business posted $3.32 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. As a group, equities research analysts forecast that Ryder System, Inc. will post 14.74 earnings per share for the current fiscal year. Ryder System Increases Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 18th. Investors of record on Monday, August 24th will be given a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This is a boost from Ryder System’s previous quarterly dividend of $0.91. This represents a $4.04 annualized dividend and a yield of 1.6%. Ryder System’s payout ratio is 29.62%.

Insider Transactions at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $251.95, for a total value of $149,910.25. Following the completion of the sale, the senior vice president directly owned 22,948 shares of the company’s stock, valued at $5,781,748.60. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.90% of the stock is owned by company insiders.

Analysts Set New Price Targets Several research firms have weighed in on R. Robert W. Baird boosted their target price on shares of Ryder System from $253.00 to $290.00 and gave the company an “outperform” rating in a research note on Wednesday, June 17th. Weiss Ratings restated a “buy (b)” rating on shares of Ryder System in a research report on Wednesday, May 27th. Citigroup lifted their price target on shares of Ryder System from $280.00 to $283.00 and gave the company a “neutral” rating in a report on Friday, July 24th. JPMorgan Chase & Co. boosted their price objective on shares of Ryder System from $259.00 to $296.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Finally, Zacks Research cut shares of Ryder System from a “strong-buy” rating to a “hold” rating in a report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Ryder System currently has a consensus rating of “Moderate Buy” and an average price target of $294.14.

Check Out Our Latest Report on Ryder System

Ryder System Company Profile (Free Report)

Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.

Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.

Recommended Stories Five stocks we like better than Ryder System Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.

Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic mild cognitive impairment, as well as Darmiyan's core technology, the Virtual Microscope, tailored towards use in pharmaceutical clinical trialsThe goal of the collaboration is to inform the identification, selection and monitoring of the best candidates for clinical trials of PEX010, Rhelion's patented, naturally derived psilocybin drug candidateToronto, Ontario--(Newsfile Corp. - August 20, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a non-binding letter of intent (the "LOI") with Darmiyan, Inc. ("Darmiyan"), a San Francisco based brain technology company, to explore a collaboration combining Darmiyan's artificial intelligence brain imaging platform with PEX010, Filament's patented, standardized, GMP manufactured natural psilocybin drug candidate.

Darmiyan is the developer of BrainSee, which in January 2024 received marketing authorization from the U.S. Food and Drug Administration ("FDA") through the De Novo pathway, following the granting of FDA Breakthrough Device Designation in 2021. Darmiyan is a graduate of the Y Combinator accelerator program (S17) and counts Y Combinator, Eisai Co., Ltd., the co-developer of Leqembi, and IT-Farm Corporation among its investors.

The De Novo pathway is the FDA route for novel, first-of-their-kind medical devices that carry low to moderate risk but have no legally marketed earlier device, known as a predicate, against which they can be compared. It allows a device to obtain marketing authorization on the strength of its own safety and effectiveness evidence, rather than through the far heavier premarket approval process reserved for high risk devices. A granted De Novo also creates a new device classification, establishing the predicate that subsequent products in the category must be measured against.

BrainSee combines a standard, non-contrast brain MRI with routine cognitive assessments to generate a prognostic score indicating the likelihood that a patient aged 55 or older with amnestic mild cognitive impairment ("aMCI") will progress to Alzheimer's dementia within five years. aMCI is an early stage of cognitive decline in which memory difficulties are measurable and noticeable to the individual and their family, but daily independence is preserved. Darmiyan's platform takes a whole-brain, microstructural view of tissue health rather than relying on a single pathological marker, and the Company believes this holistic approach is well suited to the study of agents that may act on brain plasticity and network function.

Under the LOI, the parties intend to explore the potential of applying Darmiyan's technology to improve the design of a possible future clinical study of PEX010 in individuals with early cognitive impairment who are at elevated risk of progression to Alzheimer's disease. The Company believes that AI-enabled patient selection has the potential to meaningfully reduce the number of participants, the duration, and therefore the cost of clinical research in this therapeutic area, while increasing the likelihood of detecting a treatment effect if one is present. The parties also intend to explore the use of Darmiyan's voxel-based quantitative imaging outputs as exploratory measures of biological change.

PEX010 has been selected as the investigational drug product for more than 80 academic and philanthropic research studies worldwide.

"There is a growing body of preclinical evidence that psilocybin acts as a neuroplastogen, promoting the growth and reorganization of connections between neurons," said Shashkes (Sarit Hashkes), President of Filament Health Corp. "Alzheimer's disease is, at its heart, a disease of lost connections. That makes it one of the most scientifically compelling and most underexplored questions in our field, and PEX010 is uniquely positioned to help answer it as a standardized, GMP manufactured, patent-protected botanical drug candidate already supplied to clinical research programs around the world. What excites me equally is the opportunity to work with the newest generation of AI tools. Trials in this indication have historically required enormous numbers of participants and many years to read out, which has kept the field closed to all but the largest companies. Technology like Darmiyan's has the potential to change that arithmetic, and to allow a company of our size to ask serious scientific questions in early Alzheimer's disease."

"In our aging world, perhaps more than any other field of science or medicine, Alzheimer's disease needs outside-the-box thinkers and innovators who are willing to challenge the existing paradigm and bring meaningful hope to patients, families, caregivers, and the broader industry," said Padideh Kamali-Zare, PhD, Founder and Chief Executive Officer of Darmiyan. "Despite decades of investment, progress for patients has remained limited for two main reasons. First, we have not been precise enough about whom we study or how we measure meaningful change. Second, drug development has focused primarily on biomarkers, while Alzheimer's is also a systems, network and connectivity level problem. We see strong potential for Rhelion's drug candidate to succeed, not only because of the drug itself, but also because of the team's mindset and its thoughtful approach to tackling this complex problem. Together, we look forward to examining whether the combination of Rhelion's drug candidate and our technology can make Alzheimer's research faster, smaller and more informative, ultimately accelerating the development of meaningful solutions for patients."

"When we started in this space, this was a conversation happening at the margins," said Todd Shapiro, Chief Executive Officer and Director of Rhelion. "Today we are signing a letter of intent with an FDA authorized artificial intelligence company out of Silicon Valley, backed by Y Combinator, to look at one of the most difficult diseases in medicine. That is the journey from underground to mainstream, and it is happening in real time. Exploring whether our drug candidate can contribute something to families facing Alzheimer's is exactly the kind of legacy I want this team to build. With recent research, including a case report published in Frontiers pointing to the potential benefits of natural psilocybin in a case of Alzheimer's disease, we believe this is an area that warrants serious study."

About Darmiyan, Inc.

Darmiyan, Inc. is a San Francisco based brain health technology company incorporated in September 2016 and a graduate of Y Combinator (S17). Its lead product, BrainSee, received FDA marketing authorization through the De Novo pathway in January 2024, following FDA Breakthrough Device Designation in 2021, and is a non-invasive, AI-powered prognostic test that combines standard brain MRI with routine cognitive assessment to predict progression from amnestic mild cognitive impairment to Alzheimer's dementia within five years. More information is available at www.darmiyan.com.

About Rhelion Life Sciences:

Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Examples of such information include statements with respect to: the entering into of the LOI with Darmiyan and the negotiation, execution and terms of any definitive agreement; the scope, structure and timing of any collaboration between Filament and Darmiyan; the potential application of Darmiyan's BrainSee platform, Virtual Microscope technology and voxel-based quantitative imaging outputs to clinical trial design, candidate selection, monitoring and exploratory measures; the design, initiation, conduct and completion of any future clinical study of PEX010 in amnestic mild cognitive impairment or early Alzheimer's disease; the anticipated ability of AI-enabled patient selection to reduce trial size, duration and cost or to increase the likelihood of detecting a treatment effect; the therapeutic potential of psilocybin and PEX010 in cognitive impairment, neurodegenerative disease and other indications; the properties of psilocybin as a neuroplastogen; the number of academic and philanthropic research studies under supply agreement and the continued expansion of Filament's clinical research footprint; the continued ability of Filament to manufacture and supply PEX010; and the future development, commercialization and regulatory approval of PEX010. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management as of the date hereof, are inherently subject to significant business, economic, and competitive uncertainties and contingencies.

Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the ability of Filament and Darmiyan to negotiate and enter into a definitive agreement on acceptable terms; the performance by each party of its respective obligations under any such agreement; the continued availability and regulatory status of Darmiyan's BrainSee platform; the continued ability of Filament to manufacture and supply PEX010 to research programs; the performance by counterparties of their obligations under existing supply agreements; the availability of financing on acceptable terms to fund any future clinical study; the ability to obtain and maintain any required regulatory permits and approvals, including clinical trial, ethics, import and export authorizations; and general business, market and economic conditions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, namely: the risk that no definitive agreement is entered into and that the collaboration contemplated by the LOI does not proceed; the risk that any future clinical study of PEX010 in early Alzheimer's disease is not designed, funded, initiated or completed as anticipated; the risk that Darmiyan's technology does not deliver the anticipated benefits in trial design, candidate selection or measurement; the risk that any study does not produce positive or clinically meaningful results; the risk that PEX010 does not demonstrate safety or efficacy in this or any other population; the risk that studies under supply agreement do not commence, enrol or progress as anticipated; delays in regulatory permitting, including clinical trial, ethics, import and export authorizations; regulatory or enforcement developments affecting the legal framework for psilocybin supply and research; adverse changes in the regulatory or political landscape affecting psychedelic research and access; and the other risk factors described in the Company's continuous disclosure documents available under the Company's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list is not exhaustive.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

Source: Rhelion Life Sciences Corp.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/310598

Source: Rhelion Life Sciences Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Empowered Funds LLC lessened its position in shares of Ryder System, Inc. (NYSE:R – Free Report) by 93.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,239 shares of the transportation company’s stock after selling 47,667 shares during the quarter. Empowered Funds LLC’s holdings in Ryder System were worth $663,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Ryder System by 52.8% during the first quarter. Royal Bank of Canada now owns 15,765 shares of the transportation company’s stock worth $2,267,000 after purchasing an additional 5,448 shares during the period. Focus Partners Wealth increased its holdings in Ryder System by 7.9% in the 1st quarter. Focus Partners Wealth now owns 1,851 shares of the transportation company’s stock worth $266,000 after buying an additional 135 shares during the period. Geneos Wealth Management Inc. raised its position in Ryder System by 61.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 287 shares of the transportation company’s stock worth $41,000 after buying an additional 109 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Ryder System by 10.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,191 shares of the transportation company’s stock worth $189,000 after buying an additional 110 shares during the last quarter. Finally, M&T Bank Corp lifted its stake in Ryder System by 10.9% during the 2nd quarter. M&T Bank Corp now owns 2,153 shares of the transportation company’s stock valued at $343,000 after acquiring an additional 212 shares during the period. 87.47% of the stock is owned by institutional investors and hedge funds.

Ryder System Trading Up 0.2% Shares of NYSE:R opened at $264.40 on Tuesday. The company has a current ratio of 0.65, a quick ratio of 0.65 and a debt-to-equity ratio of 1.91. Ryder System, Inc. has a 12-month low of $157.67 and a 12-month high of $284.25. The business has a 50 day moving average of $266.44 and a two-hundred day moving average of $237.32. The company has a market capitalization of $10.14 billion, a PE ratio of 21.51 and a beta of 1.02.

Ryder System (NYSE:R – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The transportation company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.69 by $0.04. Ryder System had a net margin of 3.88% and a return on equity of 18.28%. The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the company earned $3.32 EPS. The business’s revenue was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. As a group, analysts forecast that Ryder System, Inc. will post 14.74 EPS for the current year. Ryder System Increases Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 18th. Shareholders of record on Monday, August 24th will be issued a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This is a positive change from Ryder System’s previous quarterly dividend of $0.91. This represents a $4.04 dividend on an annualized basis and a yield of 1.5%. Ryder System’s dividend payout ratio is presently 32.87%.

Insider Buying and Selling at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $251.95, for a total value of $149,910.25. Following the completion of the transaction, the senior vice president owned 22,948 shares in the company, valued at approximately $5,781,748.60. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.90% of the company’s stock.

Wall Street Analysts Forecast Growth R has been the topic of a number of research reports. Robert W. Baird increased their price objective on shares of Ryder System from $253.00 to $290.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 17th. Wall Street Zen raised shares of Ryder System from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Citigroup boosted their target price on shares of Ryder System from $280.00 to $283.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Stephens raised shares of Ryder System to a “strong-buy” rating in a report on Wednesday, July 8th. Finally, Wells Fargo & Company increased their price target on Ryder System from $290.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.14.

Get Our Latest Analysis on Ryder System

About Ryder System (Free Report)

Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.

Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.

Featured Articles Five stocks we like better than Ryder System Commodities Are Booming, But These 3 ETFs Tell Different Stories 3 Active ETFs Making Big Moves in August This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.

HONG KONG, Aug 16, 2026 - (ACN Newswire) - On August 16, 2026, CanSino Biologics Inc. ("CanSinoBIO"; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years and above; the "Td5cp Adolescent and Adult") has been formally accepted by China's National Medical Products Administration (NMPA). As a booster vaccine for adolescents and adults, the product was granted Priority Review status in May 2026. If approved and launched, it is expected to create synergies with the recently approved next-generation three-component DTaP vaccine Tripecia(R) (DT3cP Infant), further strengthening CanSinoBIO's pertussis-containing vaccine portfolio across different age groups.

Pertussis is a highly contagious acute respiratory infectious disease caused by Bordetella pertussis'. In recent years, the disease has experienced a global resurgence. Data show that reported pertussis cases in China exceeded 470,000 in 2024', representing an approximately 12-fold increase compared with 2023 and drawing sustained attention to disease prevention and control. Against this backdrop, in addition to primary immunization in infants, the importance of booster immunization during adolescence and adulthood has become increasingly evident. Vaccination with diphtheria, tetanus and pertussis-containing vaccines is an important measure for preventing the related diseases, yet China has long lacked a dedicated booster immunization product for people aged six years and above.

In April this year, CanSinoBIO's Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed for infants-Tripecia(R) (DT3cP Infant)-was approved for marketing through the NMPA's Priority Review pathway, marking an important breakthrough for the company in component-based pertussis vaccine technology. Compared with the three-component (PT, FHA and PRN) DT3cP vaccine, the Td5cp Adolescent and Adult includes two additional pertussis antigens, FIM2 and FIM3. Each pertussis antigen is individually purified and formulated at precise ratios, helping ensure stable product quality and batch-to-batch consistency. The continued advancement of this product will also support further exploration of innovative component-based pertussis vaccine technology across broader age groups.

In July 2026, seven departments, including the National Disease Control and Prevention Administration and the National Development and Reform Commission, jointly issued the "15th Five-Year Plan for Disease Prevention and Control", which explicitly calls for the implementation of a life-course immunization strategy covering the entire population. As public health needs continue to evolve, providing more comprehensive immunization protection solutions for people at different stages of life has become an important direction for vaccine innovation. If the Td5cp Adolescent and Adult is successfully approved and launched, it will further enrich CanSinoBIO's pertussis-containing vaccine portfolio and support the company's continued efforts to strengthen its innovative vaccine portfolio across all age groups.

From a capital market perspective, the acceptance of the NDA for the Td5cp Adolescent and Adult marks the product's formal entry into a key regulatory review stage. It also represents important progress in CanSinoBIO's continued advancement of innovative vaccine R&D and commercialization, while strengthening market expectations for the development of the company's pipeline of combination vaccine candidates and laying a solid foundation for the company's medium- to long-term performance growth.

References:

1. Chinese Center for Disease Control and Prevention: https://www.chinacdc.cn/jkyj/mygh02/jbzt/xjxcrb/brk/202409/t20240925_300997.html

2. Zhang W, Wei C, Wan P, et al. Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China. Emerg Microbes Infect. 2026 Feb;15(1):2625556.

3. Dai H, Sui X, Che J, et al. Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficient Bordetella pertussis strains. Emerg Microbes Infect. 2026 Feb;15(1):2640283.

4. CSR data on file

Source: CanSino Biologics Inc

Copyright 2026 ACN Newswire . All rights reserved.

Ryder System, Inc. (R) Presents at Deutsche Bank's Chicago Industrials Summit Transcript

Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options.

The Company has granted an aggregate of 7,000,000 stock options to eligible participants pursuant to the Company's stock option plan. The options are exercisable at a price of C$0.265 per common share, vest over a three-year period and expire five years from the date of grant. The stock option grant is subject to acceptance by the TSX Venture Exchange.

About Theralase® Technologies Inc.:

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedarplus.ca.

Forward-Looking Statements

This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may", "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; access to sufficient capital to fund the Company's operations is available on terms that are commercially favourable to the Company or at all; the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.

For investor information on the Company, please feel to reach out Investor Inquiries – Theralase Technologies.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/308758

Source: Theralase Technologies Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Posted by Defense World Staff on Aug 4th, 2026

California State Teachers Retirement System boosted its position in Ryder System, Inc. (NYSE:R – Free Report) by 23.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,030 shares of the transportation company’s stock after purchasing an additional 9,179 shares during the period. California State Teachers Retirement System owned about 0.12% of Ryder System worth $9,832,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Royal Bank of Canada raised its position in Ryder System by 52.8% in the first quarter. Royal Bank of Canada now owns 15,765 shares of the transportation company’s stock worth $2,267,000 after acquiring an additional 5,448 shares during the period. Focus Partners Wealth grew its position in shares of Ryder System by 7.9% during the 1st quarter. Focus Partners Wealth now owns 1,851 shares of the transportation company’s stock valued at $266,000 after acquiring an additional 135 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of Ryder System by 61.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 287 shares of the transportation company’s stock worth $41,000 after purchasing an additional 109 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Ryder System by 10.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,191 shares of the transportation company’s stock worth $189,000 after purchasing an additional 110 shares in the last quarter. Finally, M&T Bank Corp raised its holdings in Ryder System by 10.9% in the 2nd quarter. M&T Bank Corp now owns 2,153 shares of the transportation company’s stock worth $343,000 after purchasing an additional 212 shares during the period. 87.47% of the stock is currently owned by institutional investors.

Insider Activity at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $251.95, for a total transaction of $149,910.25. Following the sale, the senior vice president directly owned 22,948 shares of the company’s stock, valued at $5,781,748.60. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.90% of the company’s stock.

Analyst Ratings Changes R has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price objective on Ryder System from $259.00 to $296.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Citizens Jmp assumed coverage on shares of Ryder System in a report on Wednesday, July 15th. They issued a “market perform” rating for the company. Wall Street Zen upgraded shares of Ryder System from a “hold” rating to a “buy” rating in a research note on Saturday, April 25th. Susquehanna lifted their price target on shares of Ryder System from $290.00 to $310.00 and gave the company a “positive” rating in a report on Friday, July 24th. Finally, Robert W. Baird upped their price target on shares of Ryder System from $253.00 to $290.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $294.14.

Check Out Our Latest Stock Report on Ryder System

Ryder System Stock Performance NYSE R opened at $262.77 on Tuesday. The stock has a market capitalization of $10.08 billion, a PE ratio of 21.38 and a beta of 1.02. The business has a 50 day simple moving average of $265.20 and a two-hundred day simple moving average of $232.27. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.65 and a quick ratio of 0.65. Ryder System, Inc. has a 1-year low of $157.67 and a 1-year high of $284.25.

Ryder System (NYSE:R – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.69 by $0.04. The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Ryder System had a return on equity of 18.28% and a net margin of 3.88%.The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.32 EPS. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. On average, research analysts predict that Ryder System, Inc. will post 14.74 EPS for the current fiscal year.

Ryder System Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Stockholders of record on Monday, August 24th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 1.5%. This is a positive change from Ryder System’s previous quarterly dividend of $0.91. Ryder System’s dividend payout ratio is currently 29.62%.

Ryder System Profile (Free Report)

Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.

Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.

Featured Articles Five stocks we like better than Ryder System SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Why Rare Earth Processing Could Be the Real 2027 Opportunity The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia State Teachers Retirement System Acquires 38,300 Shares of Knight-Swift Transportation Holdings Inc. $KNX

NEXT HEADLINE »Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday

-

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) CEO John Diez to address Deutsche Bank’s Chicago Industrials Summit.

Who:

Ryder System, Inc. CEO John Diez

What:

Deutsche Bank’s Chicago Industrials Summit

When:

Tuesday, August 11, 2026

Time:

3:00 p.m. Central Time

Webcast:

To access the live webcast, visit Ryder - Deutsche Bank's Chicago Industrials Summit.

About Ryder System, Inc.

Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading provider of outsourced logistics and transportation services throughout the United States, Canada, and Mexico. Ryder offers supply chain, dedicated transportation, and fleet management solutions that integrate every step of the supply chain port‑to‑door, including cross-border logistics, fleet and transportation management, warehousing and distribution, and final delivery to customers’ doorsteps. Ryder’s broad portfolio of services encompasses managed transportation, freight brokerage, dedicated contract carriage with professional drivers, full‑service fleet leasing and maintenance, commercial truck rental, automation and robotics, digital technologies, contract manufacturing and packaging, omnichannel retail fulfillment including e-commerce and last-mile delivery, and used vehicle sales. Serving more than 20 industries, Ryder manages approximately 240,000 commercial vehicles, operates nearly 800 maintenance locations, and runs approximately 320 warehouses totaling more than 100 million square feet. Ryder is consistently recognized for technology‑driven innovation and industry‑leading practices in safety, health, security, talent acquisition, and environmental management, and was most recently named to Fortune’s “America’s Most Innovative Companies” list. www.ryder.com

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

ryder-financial

More News From Ryder System, Inc.

Back to Newsroom

-

Ranks in the top 10 of TIME’s Transportation, Logistics and Aviation category, outranking industry peers among the 38 companies recognized in the sectorPlaces No. 307 among 1,000 U.S. companies evaluated for strong performance across employee satisfaction, financial performance, and sustainability transparency MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been named to TIME’s inaugural “America’s Best Companies 2026” list, ranking among the top 10 companies in the Transportation, Logistics, and Aviation category and No. 307 overall among 1,000 U.S. companies evaluated. The honor highlights Ryder’s strong financial performance, high-performing workplace culture, and commitment to sustainability—placing the company ahead of several industry peers in its category.

“Being named to TIME’s inaugural America’s Best Companies list reflects the dedication of our employees, the trust of our customers, the strength of our business, and the values that guide how we operate every day,” says John Diez, chief executive officer of Ryder. “Ranking among the top transportation and logistics companies in the country underscores our commitment to creating a workplace where employees thrive, delivering value for customers and operating responsibly in everything we do.”

The “America’s Best Companies 2026” ranking, developed by TIME and Statista, evaluates both public and private companies across three key areas:

Employee Satisfaction: Insights from approximately 217,000 employee surveys assessing workplace culture, pay, working conditions, and employer reputation. Financial Performance: Analysis of revenue growth, profitability, and asset performance over multiple years Sustainability Transparency: Evaluation of environmental, social, and governance disclosures and performance using standardized metrics and targeted research. The recognition adds to a growing list of national honors for Ryder, including a third consecutive appearance on Newsweek’s America’s Greatest Workplaces list and a second consecutive year on Fortune’s America’s Most Innovative Companies list, reinforcing the company’s reputation for workplace excellence, innovation, and operational leadership.

To view the full ranking and filter results by category, visit TIME America’s Best Companies 2026.

Ryder’s sustainability reporting includes our annual Corporate Sustainability Report (CSR) and CDP Corporate Response (CDP) which can be found at www.ryder.com/sustainability.

To learn more about Ryder’s career opportunities, visit www.ryder.com/en-us/careers.

About Ryder System, Inc.

Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading provider of outsourced logistics and transportation services throughout the United States, Canada, and Mexico. Ryder offers supply chain, dedicated transportation, and fleet management solutions that integrate every step of the supply chain port‑to‑door, including cross-border logistics, fleet and transportation management, warehousing and distribution, and final delivery to customers’ doorsteps. Ryder’s broad portfolio of services encompasses managed transportation, freight brokerage, dedicated contract carriage with professional drivers, full‑service fleet leasing and maintenance, commercial truck rental, automation and robotics, digital technologies, contract manufacturing and packaging, omnichannel retail fulfillment including e-commerce and last-mile delivery, and used vehicle sales. Serving more than 20 industries, Ryder manages approximately 240,000 commercial vehicles, operates nearly 800 maintenance locations, and runs approximately 320 warehouses totaling more than 100 million square feet. Ryder is consistently recognized for technology‑driven innovation and industry‑leading practices in safety, health, security, talent acquisition, and environmental management, and was most recently named to Fortune’s “America’s Most Innovative Companies” list. www.ryder.com

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

ryder-ar

More News From Ryder System, Inc.

Back to Newsroom

Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store

TAMPA, FL / ACCESS Newswire / July 31, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI" or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant monetization of health data by market participants, today announced that its wholly-owned online pharmacy, Corexa Pharmacy (www.CorexaRx.com/store), has begun direct-to-consumer (DTC) distribution of Tollovid®, a 3CL protease inhibitor dietary supplement, and Galactovid™, a medical food for the dietary management of galectin-1 and galectin-3 associated viral infections,

Tollovid and Galactovid are marketed by Tollo Health, LLC ("Tollo Health"), a healthcare company focused on the commercialization of nutraceuticals that address specific mechanisms of action and health IT support tools to maximize patient outcomes. Corexa Health is DataMEDS' pharmacy-focused wholly-owned subsidiary. Corexa Health has entered into a pharmacy-focused distribution arrangement with Tollo Health to make its products available through its pharmacist-supported channels and through its own Corexa Pharmacy subsidiary. DataMeds AI has separately entered into a letter of intent to acquire a controlling interest in Tollo Health, a transaction that remains subject to the negotiation of definitive agreements and customary closing conditions. There can be no assurance that it will be completed on the terms currently contemplated, or at all.

"Long COVID is a devastating physical condition that has upended the lives of tens of millions of patients worldwide, including nearly twenty million patients in the U.S. since the beginning of the pandemic according to the NIH," said Gerald E. Commissiong, Interim Co-CEO of DataMeds AI. "The treatment market for Long COVID is expected to grow from $3.2 billion in 2023 to over $32.8 billion in 2031 according to Clearview Market Insights. We attribute this massive expected growth to the development of new protocols that combine existing biopharmaceutical drugs with supplements and medical foods to help patients manage their symptoms, along with growing awareness of Long COVID and its links to related diagnoses such as Postural Orthostatic Tachycardia Syndrome (POTS), and increasingly available diagnostic tools connecting biomarker patterns to chronic pathogen response."

"We also believe it is crucial to address acute viral infections, and our portfolio of products is expected to make a meaningful impact for patients as awareness grows," Mr. Commissiong added.

Tollovid is a dietary supplement formulated to support healthy immune function, with in vitro data indicating inhibition of 3CL protease activity associated with SARS-CoV-2. Galactovid is a medical food formulated for the dietary management of viral infections associated with galectin-1 and galectin-3 activity. Corexa Health Pharmacy's pharmacists have been trained to help patients make appropriate use of these products, which are available to select pharmacists through Corexa-affiliated distribution channels.

About Tollovid®

Tollovid is an oral dietary supplement made from natural ingredients formulated to support healthy immune function and natural antiviral defense. In vitro functional assays indicate that Tollovid's ingredients bind to the active site of the 3CL protease associated with SARS-CoV-2, consistent with a supportive role following acute COVID-19 infection and in connection with Long COVID. Recommended use varies by intended purpose; consumers should refer to product labeling at www.mytollovid.com for complete usage information.

To purchase Tollovid, please visit www.CorexaRx.com/Store.

About Galactovid™

Galactovid is a medical food for the dietary management of galectin-1 and galectin-3 associated viral infections. Galactovid is formulated to inhibit galectin-1 and galectin-3 proteins, which are associated with the immune response to and cellular entry of various viruses, including SARS-CoV-2, Herpes Simplex Virus-1, and Influenza A. Galactovid's ingredients are Generally Recognized As Safe (GRAS) and may be used alongside other natural antiviral products as part of a broader management plan for acute or chronic viral infections, including those associated with Long COVID.

To purchase Galactovid, please visit www.CorexaRx.com/Store.

About Tollo Health, LLC

Tollo Health, LLC is a healthcare company developing and commercializing nature-based therapeutics, including Tollovid and Galactovid, alongside its Health Lives Here telehealth platform and TolloBio biologics development programs. Corexa Health Pharmacy, a subsidiary of DataMeds AI, Inc., distributes select Tollo Health products under a wholesale distribution arrangement.

About DataMeds AI, Inc.

DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: the Company's non-binding letter of intent to acquire a controlling interest in Tollo Health, LLC, and the anticipated timing, structure, terms and completion of that transaction; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others: the risk that the Company's proposed acquisition of a controlling interest in Tollo Health, LLC may not be completed on the anticipated terms or timeline, or at all, including because the parties have not yet executed definitive agreements; the risk that the proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to the regulatory classification and marketing claims applicable to dietary supplements and medical foods, including Tollovid and Galactovid; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DataMeds AI Media Contact

James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: [email protected]

DataMeds AI Investor Contact

Investor Relations: [email protected]

###

SOURCE: DataMEDS AI, Inc.

On July 28, 2026, Ryder System Inc (R) shares fell 3.2% to a current price of $260.13, trading within a 52-week range of $157.67 to $284.25. The recent decline

TORONTO, ON / ACCESS Newswire / July 27, 2026 / NextSource Materials Inc. (TSX:NEXT)(OTCQB:NSRCF) ("NextSource" or "the Company") is pleased to announce the positive results of an updated Technical Feasibility Study ("FS") for a Phase 2 mine expansion of its Molo Graphite Mine Project in southern Madagascar (the "Molo Mine"). The FS considered a staged expansion beyond the existing Phase 1 mining and processing operation to reach a total capacity of 150,000 tonnes per annum ("tpa") of flake graphite concentrate over a 37-year life of mine ("LOM").

Key Takeaways Ryder's Q2 EPS rose 12.4% to $3.73, while revenues increased 5% to $3.35 billion. FMS earnings and share repurchases lifted EPS, while Supply-Chain revenues climbed 8%. Ryder expects Q3 adjusted EPS of $4.00-$4.20 and narrowed 2026 guidance to $14.40-$14.80. Ryder System, Inc. (R - Free Report)  reported impressive second-quarter 2026 results, wherein both earnings and revenues surpassed the Zacks Consensus Estimate.

Quarterly earnings per share (EPS) of $3.73 beat the Zacks Consensus Estimate of $3.70 and improved 12.4% year over year, reflecting share repurchases and higher earnings in Fleet Management Solutions (“FMS”).

Total revenues of $3.35 billion beat the Zacks Consensus Estimate of $3.31 billion and rose 5% year over year. Operating revenues of $2.70 billion increased 3% year over year.

Segmental ResultsFleet Management Solutions: Total revenues of $1.56 billion inched up 6% year over year, reflecting higher fuel pricing passed through to customers and higher operating revenues. Operating revenues of $1.30 billion increased 1% year over year, reflecting contractual revenue growth, partially offset by lower commercial rental demand.

Supply-Chain Solutions: Total revenues of $1.47 billion inched up 8% year over year, reflecting increased operating revenues. Operating revenues rose 7% year over year to $1.1 billion, owing to new business, partially offset by lost business in automotive.

Dedicated Transportation Solutions: Total revenues of $600 million declined 1% year over year, while operating revenues of $455 million fell 3% year over year. The declines reflected lower operating revenues and subcontracted transportation costs passed through to customers, partially offset by higher fuel revenues.

R’s LiquidityRyder exited the second quarter with cash and cash equivalents of $219 million compared with $198 million at the quarter-end of 2026.

R’s total debt (including the current portion) was $7.46 billion at the second-quarter end compared with $7.64 billion at the end of the fourth quarter of 2025.

R’s Offers 2026 OutlookFor third-quarter 2026, Ryder expects adjusted EPS in the range of $4.00-$4.20. The mid-point of the guided range ($04.10) is above the Zacks Consensus Estimate of $3.70.

For 2026, Ryder now expects adjusted EPS in the range of $14.40-$14.80, higher than the prior guidance of $14.05-$14.80. The mid-point of the guided range ($14.60) is below the Zacks Consensus Estimate of $14.73.

Management continues to anticipate total revenues and operating revenues to increase 3% each on a year over year basis.

Adjusted ROE (return on equity) is expected to be 18%. Net cash from operating activities is still projected to be $2.7 billion. Adjusted free cash flow expectation remains unchanged at $700-$800 million. Capital expenditure is still estimated to be $2.4 billion.

Currently, Ryder carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Q2 Performances of Other Transportation CompaniesWestinghouse Air Brake Technologies (WAB - Free Report) , operating as Wabtec Corporation, reported encouraging second-quarter 2026 results, wherein both earnings and revenues surpassed the Zacks Consensus Estimate and increased year over year.

Quarterly adjusted earnings of $2.76 per share beat the Zacks Consensus Estimate of $2.63 by 4.9% and increased 21.6% year over year, owing to higher sales and operating margin expansion.

Revenues climbed 17.5% to $3.18 billion and surpassed the consensus mark of $3.08 billion by 3.2%.

United Airlines Holdings, Inc. (UAL - Free Report)  reported second-quarter 2026 adjusted earnings of $1.99 per share, down 48.6% year over year but above the Zacks Consensus Estimate of $1.92 by 3.7%.

Operating revenues rose 16% to $17.67 billion and were essentially in line with the $17.68 billion consensus mark. A 12.1% increase in total revenues per available seat mile or TRASM, and broad-based gains across premium, loyalty and cargo revenues, supported the top line despite sharply higher fuel costs.

J.B. Hunt Transport Services, Inc. (JBHT - Free Report) reported second-quarter 2026 earnings of $1.91 per share, up 45.8% from $1.31 a year ago. The figure beat the Zacks Consensus Estimate of $1.71 by 11.7%.

Operating revenues climbed 19.4% year over year to $3.50 billion and surpassed the consensus mark of $3.19 billion by 9.5%. Higher volumes and pricing across several businesses supported growth, led by a 10% increase in Intermodal loads.

On July 23, 2026, Ryder System Inc (R) shares fell 3.1% today, trading at $267.91. The stock has experienced a 52-week range between $157.67 and $284.25, reflec

Ryder (R - Free Report) reported $3.35 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 5%. EPS of $3.73 for the same period compares to $3.32 a year ago.

The reported revenue represents a surprise of +1.14% over the Zacks Consensus Estimate of $3.31 billion. With the consensus EPS estimate being $3.70, the EPS surprise was +0.81%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Ryder performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Average fleet count - ChoiceLease: 141,200 compared to the 140,812 average estimate based on two analysts.Commercial rental - Rental Utilization - Power Units: 75% versus the two-analyst average estimate of 71%.Commercial rental - Average fleet count: 29,200 versus the two-analyst average estimate of 29,912.Operating Revenue- Fleet Management Solutions: $1.3 billion compared to the $1.29 billion average estimate based on two analysts. The reported number represents a change of +1.2% year over year.Operating Revenue- Dedicated Transportation Solutions: $455 million versus $454.99 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -3.2% change.Operating Revenue- Supply Chain Solutions: $1.1 billion versus $1.08 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change.Revenues- Fleet Management Solutions: $1.56 billion versus the two-analyst average estimate of $1.5 billion. The reported number represents a year-over-year change of +6.3%.Revenues- Supply Chain Solutions: $1.47 billion compared to the $1.47 billion average estimate based on two analysts. The reported number represents a change of +7.8% year over year.Revenues- Fleet Management Solutions- SelectCare and other: $189 million versus the two-analyst average estimate of $182.4 million. The reported number represents a year-over-year change of +6.2%.Revenues- Eliminations: $-285 million versus $-268.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14% change.Revenues- Fleet Management Solutions- Commercial rental: $229 million versus $223.42 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.2% change.Revenues- Fleet Management Solutions- ChoiceLease: $885 million versus the two-analyst average estimate of $888.58 million. The reported number represents a year-over-year change of +1.6%.View all Key Company Metrics for Ryder here>>>

Shares of Ryder have returned +5.9% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) reported results for the three months ended June 30 as follows:     Earnings Before Taxes   Earnings   Diluted Earnings Per Share (In millions, except EPS)   2026   2025   2026   2025   2026   2025 Continuing operations (GAAP)   $ 185   184   $ 133   132   $ 3.40   3.15 Comparable (non-GAAP)   $ 202     193     $ 146     139     $ 3.73     3.32   Total and operating revenue for the three months ended June 30 were as follows:     Total Revenue.

In its upcoming report, Ryder (R - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $3.70 per share, reflecting an increase of 11.5% compared to the same period last year. Revenues are forecasted to be $3.31 billion, representing a year-over-year increase of 3.8%.

Over the last 30 days, there has been a downward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

With that in mind, let's delve into the average projections of some Ryder metrics that are commonly tracked and projected by analysts on Wall Street.

The consensus estimate for 'Operating Revenue- Fleet Management Solutions' stands at $1.29 billion. The estimate suggests a change of +0.5% year over year.

The average prediction of analysts places 'Operating Revenue- Dedicated Transportation Solutions' at $454.99 million. The estimate indicates a year-over-year change of -3.2%.

According to the collective judgment of analysts, 'Operating Revenue- Supply Chain Solutions' should come in at $1.08 billion. The estimate points to a change of +6.3% from the year-ago quarter.

Analysts forecast 'Revenues- Supply Chain Solutions (SCS)- Subcontracted transportation and fuel' to reach $386.04 million. The estimate suggests a change of +11.3% year over year.

Analysts predict that the 'Revenues- Fleet Management Solutions' will reach $1.50 billion. The estimate indicates a year-over-year change of +2.4%.

The collective assessment of analysts points to an estimated 'Revenues- Fleet Management Solutions- SelectCare and other' of $182.40 million. The estimate indicates a year-over-year change of +2.5%.

It is projected by analysts that the 'Revenues- Dedicated Transportation Solutions' will reach $605.39 million. The estimate indicates a change of -0.1% from the prior-year quarter.

Analysts expect 'Revenues- Fleet Management Solutions- Commercial rental' to come in at $223.42 million. The estimate indicates a change of -6.5% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenues- Fleet Management Solutions- ChoiceLease' will likely reach $888.58 million. The estimate indicates a year-over-year change of +2%.

Analysts' assessment points toward 'Revenues- Fleet Management Solutions- Fuel services' reaching $208.09 million. The estimate points to a change of +16.3% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Supply Chain Solutions' will reach $1.47 billion. The estimate suggests a change of +7.6% year over year.

Based on the collective assessment of analysts, 'Commercial rental - Rental Utilization - Power Units' should arrive at 71.0%. The estimate is in contrast to the year-ago figure of 70.0%.

View all Key Company Metrics for Ryder here>>>

Over the past month, shares of Ryder have returned +1% versus the Zacks S&P 500 composite's -0.6% change. Currently, R carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience

Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation

KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, today announced a collaboration with Curtis W. Cassidy, M.D., the inventor and developer of KetaMist® (ketamist.com), a needle-free ketamine treatment platform, to pursue U.S. Food and Drug Administration ("FDA") approval for treatment-resistant depression (TRD) and other neuropsychiatric and medical conditions where ketamine has demonstrated therapeutic benefit.

KetaMist is a proprietary, patient-controlled and needle-free ketamine treatment platform developed by Dr. Cassidy for patients with treatment-resistant depression and other conditions. According to Dr. Cassidy, KetaMist has been used in more than 9,000 patient treatments, creating a meaningful body of real-world clinical experience that PharmaTher believes may support an efficient and potentially expedited FDA development strategy.

Targeting the Large and Growing TRD Market While Building a Ketamine Franchise

Treatment-resistant depression represents a significant unmet medical need, affecting millions of patients in the United States who do not respond adequately to standard antidepressant therapies. The current FDA-approved ketamine-based therapy for TRD, Spravato® (esketamine nasal spray), has demonstrated strong commercial traction, generating approximately $1.7 billion in worldwide sales in 2025, with trailing twelve-month sales through June 30, 2026 of approximately $2.0 billion.1 Analysts have reportedly projected that Spravato could generate approximately $3 billion in annual sales by 2027 and up to $5 billion in peak annual sales, highlighting the significant commercial opportunity for differentiated ketamine-based treatments.2

PharmaTher believes KetaMist has the potential to compete in this large and growing market by offering a differentiated treatment approach that may address certain limitations associated with existing therapies.

KetaMist is designed as a patient-controlled and needle-free delivery system, which may offer several potential advantages, subject to FDA approval:

Personalized dosing and administration, allowing physicians to tailor treatment to individual patient response;Simplified delivery method, potentially improving patient comfort and accessibility;Potential for broader clinical adoption, depending on regulatory requirements and labeling; andUse of racemic ketamine, which may provide a differentiated pharmacological profile compared to esketamine.Beyond TRD, PharmaTher views KetaMist as a franchise platform with the potential to be developed across multiple indications where ketamine has already demonstrated clinical utility, including but not limited to depression, anxiety disorders, post-traumatic stress disorder (PTSD), chronic pain, and other neuropsychiatric and neurological conditions. While many of these uses are currently off-label, the Company believes KetaMist's flexible and personalized delivery approach may support expansion into additional therapeutic areas over time, subject to regulatory approval.

A Potentially Expedited Path Toward FDA Approval

PharmaTher and Dr. Cassidy plan to work with the FDA to find an efficient path to approval for KetaMist.

Because ketamine is already an FDA-approved drug, the Company may be able to build on existing knowledge. KetaMist has already been used in more than 9,000 patient treatments, providing real-world experience on how the therapy is administered, how patients respond, and overall safety. PharmaTher will prepare regulatory documents to help guide discussions with the FDA toward a potentially expedited approval pathway.

Leveraging PharmaTher's FDA-Approved Ketamine Foundation

PharmaTher previously obtained FDA approval for Ketamine Hydrochloride Injection USP under ANDA #217858, demonstrating the Company's ability to complete the regulatory, manufacturing, analytical and quality requirements necessary to secure an FDA ketamine approval.

Although PharmaTher completed its sale of its ANDA in December 2025, the Company retained its rights to pursue non-generic ketamine opportunities, including new formulations, delivery technologies and therapeutic indications. PharmaTher also retained significant regulatory and product-development experience generated through the successful ANDA program.

As part of the KetaMist collaboration, PharmaTher intends to apply its ketamine regulatory, analytical and chemistry, manufacturing and controls experience to the KetaMist development program and seek FDA feedback on the most efficient pathway toward approval.

Positioned at the Intersection of Ketamine, Personalized Medicine and Regulatory Momentum

The collaboration follows PharmaTher's recently announced strategy to advance personalized medicines for peptides and psychedelics through differentiated products, enabling technologies and regulatory pathways.

KetaMist is aligned with that strategy because its patient-controlled delivery approach is intended to allow treatment to be adjusted to individual patient response rather than relying solely on a standardized administration model.

Importantly, PharmaTher believes KetaMist's design supports its development as a multi-indication ketamine franchise, leveraging the well-established pharmacology of ketamine and its broad therapeutic potential across numerous conditions.

The program also arrives during a period of increased U.S. regulatory attention toward ketamine and innovative mental-health treatments.

PharmaTher believes that recent regulatory precedents demonstrate increasing openness to development strategies that incorporate real-world data and leverage existing clinical experience to support more efficient pathways to approval. While each program is evaluated independently by the FDA, these precedents may provide a framework for engaging with regulators on potential expedited development approaches.

"KetaMist fits our strategy perfectly-a doctor-developed ketamine treatment with over 9,000 patient uses and a path to FDA approval. While we are initially focused on treatment-resistant depression, we believe KetaMist represents a broader franchise opportunity across multiple indications where ketamine has already shown clinical benefit. By combining this real-world experience with our prior FDA-approved ketamine work, we believe we can move faster and more efficiently than traditional drug development and unlock meaningful value across several large markets," said Fabio Chianelli, Chief Executive Officer of PharmaTher.

Dr. Curtis W. Cassidy commented: "I developed KetaMist to give physicians and patients a more personalized and accessible approach to ketamine treatment. After more than 9,000 patient treatments, we have gained substantial practical experience regarding how patients respond and how treatment may be individualized across a range of conditions. PharmaTher shares that focus on personalized medicine and has the pharmaceutical-development and FDA experience needed to take the next important step toward broader access and potential regulatory approval."

Near-Term Development Priorities

The collaboration activities will include preparing an FDA meeting package to obtain guidance for a potentially accelerated path toward FDA approval.

Near-term milestones are expected to include regulatory engagement with the FDA, definition of the clinical and data requirements for a potential NDA submission, and evaluation of how existing real-world data may support the development program.

The collaboration agreement provides PharmaTher with a one-year evaluation period to assess KetaMist for potential development and commercial testing. During this period, the parties may negotiate and enter into one or more additional agreements (each a "Possible Transaction") relating to the further development and commercialization of KetaMist, subject to mutually acceptable terms.

KetaMist is not currently approved by the FDA, and its existing clinical use is considered off-label. There can be no assurance that the FDA will accept the proposed regulatory pathway, that the existing treatment information will be suitable for regulatory use, or that KetaMist will receive FDA approval.

About KetaMist®

KetaMist® is a proprietary, patient-controlled and needle-free ketamine treatment platform developed to provide a more personalized approach for patients with treatment-resistant depression and other neuropsychiatric and medical conditions. The system is designed to allow physicians to tailor dosing and administration based on individual patient response, offering flexibility compared to traditional ketamine delivery methods.

KetaMist has been used in more than 9,000 patient treatments, generating meaningful real-world clinical experience related to dosing, administration, safety observations and patient outcomes. For more information, visit Ketamist.com.

About PharmaTher

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty pharmaceutical company focused on developing, acquiring and commercializing personalized medicines and enabling technologies, with an emphasis on peptides and psychedelics. For more information, visit PharmaTher.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws, collectively referred to as "forward-looking information." Forward-looking information is often identified by words such as "believe," "expect," "plan," "intend," "may," "could," "would," "should," "anticipate," "potential," "proposed," "target," "seek," "estimate," "forecast," "position," "develop," "advance," "expedite," "accelerate," "commercialize" and similar expressions, or statements that certain events or conditions "will," "may" or "could" occur.

This press release contains forward-looking statements regarding, among other matters, the collaboration with Dr. Cassidy, the evaluation and development of KetaMist, the proposed regulatory pathway, the potential use of real-world data, future FDA interactions, required studies, intellectual-property, development, and commercial opportunities, possible transaction, and the potential submission or approval of an NDA. Forward-looking statements are based on management's current expectations and assumptions and are subject to regulatory, clinical, manufacturing, intellectual-property, financing, competitive and other risks and uncertainties. There can be no assurance that the FDA will agree with the proposed development plan, that available data will be suitable for regulatory purposes, that required studies will be successful, that sufficient financing or partnerships will be obtained, or that KetaMist will receive regulatory approval or achieve commercialization.

Forward-looking information is based on management's current expectations, estimates, forecasts, beliefs and assumptions as of the date of this news release. Material assumptions include, without limitation, that: the collaboration will remain in effect and the parties will perform their respective obligations; information regarding prior KetaMist treatments is accurate, complete, accessible and capable of being reviewed or organized for regulatory purposes; the Company will be able to engage with the FDA within anticipated timelines; the FDA will provide guidance that permits a feasible development pathway; any required studies can be designed, funded and successfully completed; suitable manufacturing, analytical, clinical and supply-chain capabilities can be obtained; the Company will have access to sufficient capital, personnel and third-party expertise; intellectual-property and commercial rights can be maintained or secured; the Company will enter into one or more possible transactions; applicable laws and regulatory policies will not change in a materially adverse manner; and market-size information, commercial estimates and third-party analyst forecasts referenced in this news release are reasonably accurate. These assumptions may prove to be incorrect. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, events or achievements to differ materially from those expressed or implied. Such risks include, without limitation: the possibility that the FDA may not agree with the Company's proposed development or regulatory strategy; that KetaMist may not qualify for an expedited or accelerated pathway; that the FDA may require substantial additional non-clinical, clinical, manufacturing, human-factors or other studies; that real-world data or information from prior patient treatments may be incomplete, inconsistent, retrospective, unverifiable or unsuitable for regulatory reliance; that existing treatment experience may not demonstrate safety or efficacy to the FDA's satisfaction; that studies may be delayed, unsuccessful or more costly than expected; and that KetaMist may never receive regulatory approval.

Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company's continuous disclosure filings available under the Company's profile on SEDAR+. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Footnotes

Johnson & Johnson, "Johnson & Johnson Reports Q4 and Full-Year 2025 Results," January 21, 2026, reporting worldwide Spravato sales of $1.696 billion for the year ended December 31, 2025; and Johnson & Johnson, "Johnson & Johnson Reports Q2 2026 Results, Raises 2026 Outlook," July 15, 2026, reporting worldwide Spravato sales of $1.052 billion for the six months ended June 30, 2026, compared with $734 million for the corresponding six-month period in 2025. Trailing twelve-month sales through June 30, 2026 were calculated as follows: $1.696 billion less $734 million, plus $1.052 billion, equalling approximately $2.014 billion. Figures may not add precisely due to rounding."Johnson & Johnson's Spravato Sales Growth Signals Upside for Psychedelic Drug Opportunity: Jefferies," April 14, 2026. The report stated that Jefferies projected Spravato annual sales of approximately $3 billion by 2027, $3.5 billion by 2028 and potential peak annual sales of up to $5 billion. These projections are analyst estimates and are not guarantees of future performance.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305777

Source: PharmaTher Holdings Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways R hiked its quarterly dividend by 10.9% to $1.01 per share, payable on Sept. 18 to shareholders as of Aug. 24.This marks R's 200th consecutive quarterly dividend, continuing over 50 years of uninterrupted payouts.Dividend-paying stocks are less susceptible to market swings and act as a hedge against economic uncertainty. Last week, Ryder System, Inc. (R - Free Report) ) stated that its board of directors had announced an increase in its quarterly dividend payout, reflectingthe company’s commitment to boosting shareholder value, apart from underlining confidence in its business. 

Dividend-paying stocks provide a solid income stream and have fewer chances of experiencing wild price swings. Dividend stocks are safe bets for creating wealth, as the payouts generally act as a hedge against economic uncertainty, like the current scenario. 

Given this backdrop, the question that naturally arises is: Should investors buy, hold, or sell Ryder stock now? A more in-depth analysis is needed to make that determination. Before diving into Ryder’s investment prospects, let’s take a glance at its financial numbers.

Ryder’s Recent Dividend Increase of 10.9%In a shareholder-friendly move, Ryder’s board of directors has approved a dividend hike of 10.9%, thereby raising its quarterly cash dividend to $1.01 per share ($4.04 annualized) from 91 cents ($3.64 annualized). The raised dividend will be paid on Sept. 18, 2026, to shareholders of record as of the close of business on Aug. 24, 2026. The move reflects R’s intention to utilize free cash to enhance its shareholders’ returns.

R's latest dividend hike is the first increase since July 2025, implying the company’s confidence in its financial footing. This marks Ryder’s 200th consecutive quarterly cash dividend. Notably, Ryder has been making uninterrupted dividend payments for more than 50 years.

Ryder has been making uninterrupted dividend payments for more than 48 years. Ryder’s bottom line has been benefiting from its consistent efforts to reward its shareholders through dividends and share buybacks. During 2022, Ryder paid dividends of $123 million and repurchased shares worth $557 million. In 2023, Ryder paid dividends of $128 million and repurchased shares worth $337 million. In 2024, Ryder returned $456 million in cash to shareholders through share repurchases and dividends. During 2025, Ryder returned $664 million to shareholders through share repurchases and dividend payments. During first-quarter 2026, Ryder returned $272 million to shareholders in the form of share repurchases and dividends.

Apart from being shareholder-friendly, Ryder is well-served by its focus on contractual growth and operational discipline. Upbeat used vehicle sales, particularly in its fleet management segment, along with stable pricing and improved contractual sales activity, bode well.

Ryder's cost-cutting initiatives in response to the weak freight market conditions are also commendable. Higher free cash flow generation expectation (this reflects lower capital spending due to softer lease sales activity) for the full year is another added positive. Ryder generated $2.59 billion of cash from operating activities in 2025, higher than the $2.26 billion generated in 2024. For 2026, adjusted ROE (return on equity) is expected to be in the range of 17-18%. Net cash from operating activities is still projected to be $2.7 billion.

Ryder Stock’s Price PerformanceShares of Ryder have gained 40.5% so far this year, outperforming the Zacks  Transportation - Equipment and Leasing industry’s 11.8% increase, as well as that of other industry players, The Greenbrier Companies, Inc. (GBX - Free Report) and Wabtec Corporation (WAB - Free Report) .

Ryder Stock’s YTD Price Comparison Image Source: Zacks Investment Research

Attractive Valuation Picture for Ryder StockRyder looks cheap from a valuation standpoint. Considering the forward 12-month price-to-sales ratio (P/S-F12M), Ryder is trading at a discount compared to the industry.

The stock has a forward 12-month P/S-F12M of 0.76X compared with 2.26X for the industry over the past five years. These factors indicate that the stock’s valuation is attractive. Ryder has a Value Score of A.

Ryder P/S Ratio (Forward 12 Months) Vs. Industry Image Source: Zacks Investment Research

What Do Earnings Estimates Say for Ryder?The positive sentiment surrounding Ryder stock is evident from the fact that the Zacks Consensus Estimate for the third quarter of 2026 and the fourth quarter of 2026 earnings has been revised upward in the past 90 days. The consensus mark for 2026 and 2027 earnings has also been projected northward in the past 90 days.

The favorable estimate revisions indicate brokers’ confidence in the stock.

Image Source: Zacks Investment Research

Time to Buy Ryder StockApart from being attractively valued, Ryder stock is being well-served by its focus on contractual growth and operational discipline. Upbeat used vehicle sales, particularly in its fleet management segment, along with stable pricing and improved contractual sales activity, bode well. Initiatives to reward its shareholders through dividends and buybacks are praiseworthy as well.

We believe that the positives surrounding the stock (as highlighted throughout the write-up) outweigh the concerns regarding supply-chain disruptions and high fuel costs due to the ongoing conflict in the Middle East, tariff-induced economic uncertainties, risks associated with an economic slowdown, geopolitical tensions and a leveraged balance sheet. We, therefore, suggest investors add Ryder stock to their portfolios for healthy returns. The company’s Zacks Rank #2 (Buy) further supports our thesis. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.